Novartis raises full year core operating income guidance
27/10/2026 06:03
Novartis raises full year core operating income guidance ZURICH/LONDON, Oct 26 (Reuters) - Novartis NOVN.S raised its full-year core operating income guidance on Tuesday after strong third-quarter demand for its key cancer and multiple sclerosis drugs.
The Swiss drugmaker now expects core operating income to grow by a low single-digit percentage compared to the low single-digit decline previously expected. It maintained its forecast for low single-digit net sales growth.
(Reporting by Bhanvi Satija and Marleen Kaesebier, Editing by Friederike Heine)
((Bhanvi.Satija@thomsonreuters.com; +44 7916316907;))
Recent news on Novartis AG
See all newsEurope Research Roundup: Ambu, Intesa Sanpaolo, Solvay
Swiss pharma industry behind in technology and clinical trials, index shows
European shares rise as Democrats take US Congress, Novo Nordisk surges
European shares rise as Democratic sweep lifts clean energy, bank stocks
Europe set to open lower as Democratic sweep fuels AI regulation fears